StockData
Guided Therapeutics Inc logo

Guided Therapeutics Inc (GTHP) stock

GTHPOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 4/30
$0.16−0.03 (-15.79%)

Close on Oct 19, 2026Market cap $15.45MP/E –Yield –

Guided Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Guided Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$1.98M. For fiscal 2025 it was -$2.37M. The highest annual figure on record is -$937.00K in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$2.37M–
FY2024Dec 31, 2024-$2.11M–
FY2023Dec 31, 2023-$3.46M–
FY2022Dec 31, 2022-$3.33M–
FY2021Dec 31, 2021-$2.36M–
FY2020Dec 31, 2020-$1.05M–
FY2019Dec 31, 2019-$937.00K–
FY2018Dec 31, 2018-$1.55M–
FY2017Dec 31, 2017-$3.12M–
FY2016Dec 31, 2016-$3.82M–
FY2015Dec 31, 2015-$6.23M–
FY2014Dec 31, 2014-$8.67M–
FY2013Dec 31, 2013-$6.61M–
FY2012Dec 31, 2012-$4.28M–
FY2011Dec 31, 2011-$6.76M–
FY2010Dec 31, 2010-$1.62M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$478.00K–
Q1 FY2026Mar 31, 2026-$302.00K–
Q4 FY2025Dec 31, 2025-$710.00K–
Q3 FY2025Sep 30, 2025-$485.00K–
Q2 FY2025Jun 30, 2025-$763.00K–
Q1 FY2025Mar 31, 2025-$414.00K–
Q4 FY2024Dec 31, 2024-$534.00K–
Q3 FY2024Sep 30, 2024-$561.00K–
Q2 FY2024Jun 30, 2024-$655.00K–
Q1 FY2024Mar 31, 2024-$359.00K–
Q4 FY2023Dec 31, 2023-$485.00K–
Q3 FY2023Sep 30, 2023-$623.00K–
Q2 FY2023Jun 30, 2023-$1.51M–
Q1 FY2023Mar 31, 2023-$843.00K–
Q4 FY2022Dec 31, 2022-$948.00K–
Q3 FY2022Sep 30, 2022-$1.22M–
Q2 FY2022Jun 30, 2022-$717.00K–
Q1 FY2022Mar 31, 2022-$443.00K–
Q4 FY2021Dec 31, 2021-$435.00K–
Q3 FY2021Sep 30, 2021-$487.00K–
Q2 FY2021Jun 30, 2021-$561.00K–
Q1 FY2021Mar 31, 2021-$823.00K–
Q4 FY2020Dec 31, 2020-$288.00K–
Q3 FY2020Sep 30, 2020-$153.00K–
Q2 FY2020Jun 30, 2020-$369.00K–
Q1 FY2020Mar 31, 2020-$242.00K–
Q4 FY2019Dec 31, 2019-$165.00K–
Q3 FY2019Sep 30, 2019-$188.00K–
Q2 FY2019Jun 30, 2019-$327.00K–
Q1 FY2019Mar 31, 2019-$257.00K–
Q4 FY2018Dec 31, 2018-$449.00K–
Q3 FY2018Sep 30, 2018-$234.00K–
Q2 FY2018Jun 30, 2018-$491.00K–
Q1 FY2018Mar 31, 2018-$376.00K–
Q4 FY2017Dec 31, 2017-$731.00K–
Q3 FY2017Sep 30, 2017-$1.34M–
Q2 FY2017Jun 30, 2017-$533.00K–
Q1 FY2017Mar 31, 2017-$514.00K–
Q4 FY2016Dec 31, 2016-$1.11M–
Q3 FY2016Sep 30, 2016-$679.00K–

More Guided Therapeutics figures

See a number that looks wrong?